Objective:

To investigate the immunological effects of intravenous (i.v.) ocrelizumab versus subcutaneous (s.c.) ofatumumab in people with multiple sclerosis (pwMS).

Approach:

Key Findings:

• Both anti-CD20 therapies resulted in significant depletion of CD19+ B cells and CD20+ T cells in pwMS.
• Higher percentages of memory B cells were observed in pwMS treated with s.c. Ocre and Ofa compared to those treated with i.v. Ocre (p < 0.05).
• In pwMS switching from i.v. Ocre to s.c. Ofa, the percentage of memory B cells increased over time (p < 0.05).

Interpretation:

The study highlights distinct immunomodulatory effects of s.c. versus i.v. anti-CD20 therapies in pwMS, particularly regarding memory B cell proportions, which may influence treatment strategies.

Limitations:

• The sample size for each treatment group was limited to 25 pwMS, which may affect the generalizability of the findings.
• Further analysis is needed to link findings to safety and efficacy profiles of different anti-CD20 therapies.

Conclusion:

The findings contribute to understanding the immunological differences between i.v. and s.c. B-cell depletion therapies in MS.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.